New eye drug PMC-403 tested in humans for first time
NCT ID NCT05953012
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new drug called PMC-403 in 17 people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. The drug is injected directly into the eye. The main goal was to check safety and find the best dose for future studies. The trial is now complete, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PMC-403 (injected into the eye)
What this could lead to
If safe, this could lead to a new treatment option for wet age-related macular degeneration, potentially offering an alternative to current therapies.
What could go wrong
This is a very early Phase 1 trial with only 17 people, focused on safety, not effectiveness. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASAN Medical Center
Seoul, Songpa-gu, 05505, South Korea
-
Seoul National University Bundang Hospital
Seoul, Bundang-gu, 13620, South Korea
-
Yeungnam University
Daegu, Nam-gu, 42415, South Korea
-
Yonsei University Health System
Seoul, Seodaemun-gu, 03722, South Korea